176 Chapter 7 28. Whitwell JL, Tosakulwong N, Weigand SD, Graff-Radford J, Duffy JR, Clark HM, et al. Longitudinal Amyloid-β PET in Atypical Alzheimer’s Disease and Frontotemporal Lobar Degeneration. J Alzheimers Dis. 2020;74(1):377-89. 29. Hatashita S, Wakebe D, Kikuchi Y, Ichijo A. Longitudinal Assessment of Amyloid-β Deposition by [18F]-Flutemetamol PET Imaging Compared With [11C]-PIB Across the Spectrum of Alzheimer’s Disease. Frontiers in aging neuroscience. 2019;11:251-. 30. Jack CR, Jr., Wiste HJ, Weigand SD, Therneau TM, Knopman DS, Lowe V, et al. Age-specific and sex-specific prevalence of cerebral beta-amyloidosis, tauopathy, and neurodegeneration in cognitively unimpaired individuals aged 50-95 years: a cross-sectional study. Lancet Neurol. 2017;16(6):435-44. 31. Ingala S, De Boer C, Masselink LA, Vergari I, Lorenzini L, Blennow K, et al. Application of the ATN classification scheme in a population without dementia: Findings from the EPAD cohort. Alzheimers Dement. 2021;17(7):1189-204. 32. Eckerström C, Svensson J, Kettunen P, Jonsson M, Eckerström M. Evaluation of the ATN model in a longitudinal memory clinic sample with different underlying disorders. Alzheimer’s & dementia (Amsterdam, Netherlands). 2021;13(1):e12031-e.